Conference Coverage
Conference Coverage
Drug that fell short in prostate cancer could treat MM
PHILADELPHIA—A drug that has fallen short of expectations in clinical trials of prostate cancer may be effective for treating multiple myeloma (MM...
Conference Coverage
ASA: Tumors glow green in new ‘optical biopsy’ technique
Key clinical point: Fluorescein-tagged tumors glowed visibly and allowed accurate detection of pulmonary adenocarcinomas. Major finding: A novel...
Conference Coverage
‘Watch and wait’ may be inadvisable for CLL
PHILADELPHIA—Withholding treatment from chronic lymphocytic leukemia (CLL) patients because they are of advanced age and have comorbidities may...
Conference Coverage
Check sweat glands, hair follicles in mycosis fungoides
Key clinical point: Routinely check mycosis fungoides patients for sweat gland and hair follicle involvement. Major finding: Among 34mycosis...
Conference Coverage
EBV-CTLs produce durable responses in EBV-LPD
among uninfected cells (blue) Image courtesy of NIH/ Benjamin Chaigne-Delalande PHILADELPHIA—Cytotoxic T lymphocytes designed to target Epstein-...
Conference Coverage
Avoid voriconazole in transplant patients at risk for skin cancer
Key clinical point: Use an alternative antifungal after lung transplant in white men aged 50 years and older.
Conference Coverage
VIDEO: Sun protection urged for Asian, Hispanic women
Conference Coverage
‘Biodegradable’ CAR may aid transplant in AML
Photo courtesy of BMT Tandem Meetings SAN DIEGO—Researchers have developed a “biodegradable” chimeric antigen receptor (CAR) T-cell therapy that...
Conference Coverage
Drug shows promise for treating VOD after HSCT
Photo by Chad McNeeley SAN DIEGO—Results of 3 studies appear to support the use of defibrotide in patients who develop hepatic veno-occlusive...
Conference Coverage
Testicular cancer history ups risk for higher-risk prostate cancer
Key clinical point: A history of testicular cancer appears to be a risk factor for intermediate- to high-risk prostate cancer.
Conference Coverage
Haplo-BMT feasible in high-risk malignancies
Photo by Chad McNeeley SAN DIEGO—Haploidentical bone marrow transplant (haplo-BMT) is a feasible option for patients with high-risk hematologic...